Syndros Solution
NDC Package 85776-201-30

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Syndros (dronabinol) solution is dronabinol is used to treat nausea and vomiting caused by cancer chemotherapy. This formulation utilizes a solution delivery system. Marketed by Wellhouse Pharma, Llc, this product is identified by NDC 85776-201 and is authorized under FDA application NDA205525.

Identification & Billing

NDC Package Code
85776-201-30
Package Description
1 BOTTLE, GLASS in 1 CARTON / 30 mL in 1 BOTTLE, GLASS
Product Code
85776-201
11-Digit Billing Format
85776020130
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Syndros
Non-Proprietary Name
Dronabinol
Substance Name
Dronabinol
Dosage Form
Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
DRONABINOL 5 mg/mL
Pharmacologic Class
Usage Information
Dronabinol is used to treat nausea and vomiting caused by cancer chemotherapy. It is used when other drugs usually used to control nausea and vomiting have not worked well. Dronabinol is also used to treat loss of appetite and weight loss in people with HIV infection. Dronabinol (also called THC) is a man-made form of a natural substance in marijuana (cannabis).
DEA Schedule
Schedule II (CII) Substances

Regulatory & Marketing

Labeler Name
Wellhouse Pharma, Llc
Product Type
Human Prescription Drug
FDA Application #
NDA205525
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
04-16-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 85776-201-30 identifies a specific commercial package of 1 bottle, glass in 1 carton / 30 ml in 1 bottle, glass of Syndros, a human prescription drug labeled by Wellhouse Pharma, Llc. This solution is formulated for oral use and contains dronabinol as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Wellhouse Pharma, Llc on April 16, 2026. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Dronabinol is used to treat nausea and vomiting caused by cancer chemotherapy. It is used when other drugs usually used to control nausea and vomiting have not worked well. Dronabinol is also used to treat loss of appetite and weight loss in people with HIV infection. Dronabinol (also called THC) is a man-made form of a natural substance in marijuana (cannabis).

How is this Wellhouse Pharma, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 85776020130. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
85776-201-30
11-Digit CMS (5-4-2)
85776-0201-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.